SKLB610 is a small-molecule inhibitor primarily investigated for its potential in cancer therapy. It functions by targeting specific kinase pathways involved in tumor cell proliferation and survival, showing particular activity against receptor tyrosine kinases that are often overexpressed in various cancers. Due to its ability to inhibit angiogenesis and induce apoptosis in cancer cells, SKLB610 has been studied in preclinical models for solid tumors, including lung, liver, and colorectal cancers. Its application is focused on developing targeted therapies with improved selectivity and reduced side effects compared to conventional chemotherapy. Research continues to evaluate its efficacy, pharmacokinetics, and potential for clinical translation.